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Epidermal growth factor receptor (EGFR) gene mutational analysis is critical for guiding the treatment of lung adenocarcinoma. In everyday clinical practice, EGFR testing is frequently centralized in referral
The epidermal growth factor receptor (EGFR) gene encodes a transmembrane growth factor receptor with tyrosine kinase activity that regulates cell proliferation and survival by activating downstream Ras/Raf/Map kinase pathways. [1] [2] [3] [4] Some specific somatic mutations of the tyrosine kinase domain of EGFR predict the response to EGFR tyrosine kinase inhibitors in a subset of patients with non-small cell lung cancers (mainly adenocarcinomas). [4] [5] [6] It is therefore essential to screen for EGFR mutations to select potential responders.
Polymerase chain reaction (PCR) amplification of DNA extracted from tumor samples, followed by the sequencing of the amplified product, is widely used to detect EGFR mutations in clinical practice. However, this method is limited by its relatively low sensitivity (10% of mutated DNA against a background of wild-type [WT] genomic DNA) and requires samples containing large numbers of tumor cells (200-400 cells) that mainly come from biopsy or surgical samples. 5 The presence of metastatic or locally advanced disease means that fewer than 30% of lung adenocarcinomas are surgically resectable at the time of diagnosis, and lung biopsies are often poorly tolerated by patients with lung cancer. Therefore, cytologic specimens are often the only samples available for both diagnostic and molecular purposes. [7] [8] [9] [10] Consequently, more sensitive assays and more precise methods of selecting cancer cells in cellularly heterogeneous samples are necessary to obtain sufficient DNA for EGFR mutational analysis, particularly if the samples have a limited number of tumor cells or are not optimally fixed. 5 Furthermore, EGFR molecular analyses are often carried out in centralized laboratories that receive various types of samples from outside hospitals (fine-needle aspiration, bronchoalveolar lavage, pleural effusion, and sputum samples), which may be processed using different fixatives and inclusion media.
The aim of this study was to evaluate the feasibility of establishing EGFR mutational status in diagnostic cytologic specimens of lung adenocarcinomas using 2 combined technologies: the amplified refractory mutation system (ARMS) and real-time PCR performed using Scorpion chemistry. In particular, we tried to identify: (1) the smallest number and percentage of neoplastic cells required for mutational analysis; and (2) whether the fixatives commonly used in cytology are suitable for this assay
Materials and Methods
Patients and Samples
A total of 108 cytologic samples of lung adenocarcinomas were analyzed between May 2010 and October 2011: 87 (80.6%) from primary tumors, 20 (18.5%) from metastatic regional lymph nodes, and 1 (0.9%) from the peritoneal cavity. The samples were collected at various hospitals located in the Eastern Piedmont (Italy) and Canton Ticino (Switzerland) regions. Eighty (74.1%) were obtained using fine-needle aspiration (FNA), 13 (12%) from pleural and ascitic fluids, 13 (12%) by means of bronchial washing, and 2 (1.9%) by means of bronchial brushing.
The preanalytical protocols used for processing the samples varied depending on the type of specimen and the originating hospital. All of the FNAs were performed using disposable 21-or 22-gauge needles, but their methods of preparation varied considerably. The FNA samples from Locarno (Switzerland) were processed using the liquid-based, thin-layer cytology ThinPrep 2000 method (Hologic, Marlborough, MA). The material was fixed using Cytolyt hemolytic and preservative solution (Hologic), after which the cells were centrifuged at 1,800g and the sediment was transferred to Preservcyt solution (Hologic) before being processed in a T200 automated processor (Hologic) in accordance with the manufacturer's recommendations; finally, the slides were spray fixed using ethanol (Bio-Fix, Bio Optica, Milan, Italy). The FNA smears from Eastern Piedmont were immediately transferred to a glass slide and spray fixed. Some of the needle content was also washed in lysing solution and centrifuged at 1,800g to prepare cell blocks in 1 of 2 ways depending on the routine practice of the institution sending them: some used agarose gel with ethanol fixation, and others used human plasma and thrombin with buffered formalin fixation to congeal the cell pellet.
The bronchial washing and fluid specimens were centrifuged to obtain a cell pellet, part of which was transferred to a glass slide and spray fixed, and the rest was fixed with a mixture of alcohol formol or Duboscq-Brasil fluid for 24 hours. Subsequently, paraffin-embedded cell blocks were prepared and sectioned.
The bronchial brushing specimens were prepared by rolling the end of the brush on a glass slide, and immediately spray fixed.
All of the samples obtained by transferring smears to glass slides were stained with the Papanicolaou stain and permanently mounted, whereas the sections obtained by cutting paraffin-embedded cell blocks were stained with H&E, and investigated with immunohistochemical analysis when a definition of the histotype was required.
DNA Extraction and Molecular Analysis
All 108 samples underwent EGFR mutational analysis regardless of the number or concentration of cancer cells or how they were processed. Under microscopic control, the cancer cells from the Papanicolaou-stained samples were scraped from the glass slides using a surgical blade after removing the cover slide by means of overnight incubation in xylene. Based on stochastic distribution of the malignant and nonmalignant cells in the cell block, inclusions were manually dissected after selecting the areas containing the maximum number and concentration of cancer cells; this was done using a marker for the H&E-stained sections or without any selection when the 2 cell populations were intermixed. The scraped cells or dissected areas were then placed inside a sterile tube and DNA was extracted using the commercially available MagneSil genomic fixed tissue system (Promega, Madison, WI) in Eastern Piedmont (Italy) and the QIAamp mini kit (Qiagen, Manchester, England) in the Cantonal Institute of Pathology (Locarno, Switzerland).
Molecular analysis of the samples was performed using the TheraScreen EGFR29 mutation kit (Qiagen), which combines the 2 technologies of ARMS and Scorpion chemistry to detect mutations using real-time PCR. This kit allows in-frame deletions on exon 19, insertions on exon 20, and G719X, S768I, L858R, and L861Q mutations to be detected against a background of WT genomic DNA. All of the reactions were performed in 25-mL volumes containing 2.5 mL of the template DNA extracted from the cytologic samples, 20 mL of reaction mix, and 2.5 mL of nuclease-free water (Promega) using a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA).
The EGFR results were recorded as nonamplified (when the threshold cycle of the control reaction was ≥40); negative (WT) sample (when only the control reaction was amplified); or positive (mutated), when both the control reaction and one of the mutational reactions were amplified.
To establish the minimum number of cells required for successful EGFR DNA sequence analysis, the positive samples were retrospectively reviewed by 2 pathologists (R.B., G.M.). Cancer cellularity and the mean percentage of cancer cells in each population of total nucleated cells were evaluated independently by counting the exact numbers of cancer cells on the slide and defined after a consensus microscopic session. Cancer cellularity was defined as the exact number when the cancer cells were fewer than 20; as a numerical range when they were more than 20: 20 to 49, 50 to 99, 100 to 199, 200 to 499, 500 to 999; and more than 1,000 cells.
Results
Adenocarcinoma was diagnosed with a routine morphologic examination (about 80% of the cases) or by using a 4-antibody panel that included thyroid transcription factor 1, cytokeratin 7, p63, and cytokeratins 5 and 6, as proposed by Righi et al. 11 Of 108 cytologic samples, 92 (85.2%) were amplified and 16 (14.8%) were not. Seventy (76.1%) of the 92 amplified samples were negative for EGFR mutations, and 22 (23.9%) were positive: 14 (63.6%) with deletions on exon 19; 6 (27.3%) with a mutated exon 21, including L858R (n = 5) and L861Q mutations (n = 1); 1 (4.5%) with a mutated exon 18 (G719X); and 1 (4.5%) with insertions in exon 20.
❚Table 1❚ shows the feasibility of the EGFR mutation analysis in relation to the type of specimen, the fixation medium, and the processing method. Of the 16 nonamplified samples, 10 were from FNA biopsies, 5 from bronchial washing fluid, and 1 from pleural fluid. The formalin-fixed samples and the only fresh sample were all amplified successfully, whereas EGFR mutation analysis was not possible in 6 (33.3%) of the 18 Duboscq-Brasil samples and 10 (12.7%) of the 79 ethanol-fixed samples. Interestingly, all of the cases processed by means of thin-layer cytology were suitable for analysis, and manual scraping from spray-fixed specimens on glass slides allowed a sufficient number of cells to be obtained in 8 (72.7%) of 11 cases.
❚Table 2❚ shows the number and mean percentage of neoplastic cells in the EGFR-positive samples. EGFR mutations were found in 9 samples containing fewer than 200 cancer cells and in 4 samples in which the mean percentage of cancer cells was less than 50%. It is interesting to note that EGFR mutation analysis was possible in case 19, in which the deletion of exon 19 was identified in fewer than 16 neoplastic cells in a sample containing only 20% neoplastic cells.
❚Table 3❚ shows the number and mean percentage of neoplastic cells in the nonamplified samples. EGFR mutation analysis failed in 4 samples containing more than 200 cancer cells and in 7 samples in which the mean percentage of cancer cells was more than 50%. The 6 samples fixed with Duboscq-Brasil (for which we were unable to amplify DNA) contained a low percentage (<50%) and/or small number of cancer cells (<100).
Discussion
The findings of this study show that EGFR mutation analysis is feasible in most cytologic specimens obtained using routine diagnostic procedures (including cell blocks from FNA biopsy samples, pleural and ascitic fluids, and bronchial washing and bronchial brushing fluids) or by scraping cancer cells from diagnostic glass slides. The practical importance of these results lies in the possibility of obtaining sufficient good-quality DNA for EGFR testing from cytologic samples taken during the course of diagnostic procedures, even when they were characterized by a small number and/or a low percentage of neoplastic cells or processed using unconventional or nonoptimal fixatives.
EGFR mutations were found in 9 samples containing fewer than 200 cancer cells and in 4 samples in which the mean percentage of cancer cells was less than 50%. The European Workshop on EGFR Mutation Testing 5 suggested that, although ill-defined, the minimum number of tumor cells required for adequate testing is at least 200 to 400, and the minimum percentage, at least 50%. The panel therefore discouraged the use of cytologic samples and strongly recommended that clinicians should provide biopsy samples "whenever possible." 5 These statements are based on the general idea that direct sequencing is the "gold standard" for research trials and in the clinical detection of EGFR mutations, mainly because it is inexpensive and widely available. However, it is less sensitive than other target methods. A meta-analysis by da Cunha Santos et al 8 of EGFR mutation analyses in cytologic samples of non-small cell lung carcinomas found that the results of direct sequencing (used in 18 of 25 studies) correlated poorly with those obtained from paired surgical specimens. For example, Smouse et al 7 were unable to obtain sufficient DNA for mutational analysis from 6 (33%) of 18 cytologic samples as opposed to only 18 (7.4%) of 245 unamplified samples from surgical specimens; in their molecular analysis of 35 patients, Schuurbiers et al 12 failed in 8 cases because of insufficient material after routine and immunocytochemical staining (n = 3), fewer than 40% tumor cells (n = 3), or poor quality DNA (n = 2).
Our results were obtained using Scorpion ARMS technology, which is based on the preferential amplification of the excess mutant allele. Because it can detect 1% of mutated EGFR against a WT background, this method requires only a few neoplastic cells even in cellularly heterogeneous samples such as cytologic specimens. We even detected an EGFR mutation (Del exon 19) in a sample of bronchial washing fluid containing only 16 cancer cells against a wide background of normal cells (20% of cancer cells). Similar results have been obtained by Savic et al 13 and Molina-Vila et al, 14 who detected EGFR mutations in as few as 30 and 8 cancer cells, respectively, using laser capture microdissection. Although these results as well as ours could have been obtained by chance, they seem to indicate that the minimum number and percentage of cells required to detect EGFR mutations should be adjusted on the basis of the sensitivity of the assay.
The main limitations of Scorpion ARMS include the possibility of detecting background mutations that are irrelevant in clinical practice and, above all, the impossibility of detecting untargeted mutations, such as the mutation of pharmacologic resistance (T790 in exon 20) or other novel mutations.
We studied various types of cytologic specimens that were heterogeneously processed because they came from outside hospitals. On the whole, we obtained sufficient DNA for EGFR mutation testing in a high percentage of cases (85%), whereas DNA could not be amplified in only 16. The worst results were obtained using bronchial washing fluid (5/8 samples were inadequate), whereas pleural and ascitic fluids, FNA samples, and the 2 samples of bronchial brushing fluid led to better results. Surprisingly, we obtained sufficient DNA for mutational analysis from 12 of the 18 specimens fixed in Duboscq-Brasil which, although it preserves morphologic details better and has been used in the cytologic examination of hardening cell blocks, contains picric acid. Like Bouin fixative, its use is discouraged by the European Panel on EGFR Mutation Testing, 5 which indicated formalin as the optimum fixative for mutation analysis.
Although our findings cannot be compared with other published results and therefore need further confirmation, they suggest that in some cases Duboscq-Brasil is capable of preserving DNA at least as well as other fixatives. Because the 6 samples fixed in Duboscq-Brasil in which we were unable to amplify DNA included 5 bronchial washing samples and 1 fluid sample with a low percentage or small number of cancer cells, the lack of DNA amplification may have resulted from the small number of DNA copies in the specimen rather than the degradation induced by the fixative. EGFR mutation analysis was perfectly feasible in 8 of the 11 samples obtained by scraping cells from diagnostic glass slides by means of manual microdissection using a surgical blade. This confirms previous findings by Boldrini et al, 15 who obtained information on EGFR mutations in a large proportion of their cytologic smears using a 25-gauge needle for the microdissection, and Betz et al, 16 who successfully analyzed both EGFR and KRAS mutations in 33 fresh and archived smears of lung carcinomas. These methods have the advantage of retrieving information from archived cases inexpensively, even when smears are the only material available.
In conclusion, our findings indicate that cytologic specimens are adequate for EGFR mutation analysis when a highly sensitive molecular assay is used, and suggest that mutational analysis should be attempted even in samples with poor cellularity or which have been processed using fixatives that have so far been considered unsuitable.
